Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from BerGenBio ASA ( (BRRGF) ) is now available.
BerGenBio ASA has completed its merger with Oncoinvent ASA, resulting in the dissolution of Oncoinvent and the renaming of BerGenBio to Oncoinvent ASA. This merger, registered with the Norwegian Register of Business Enterprises, involves the issuance of 117,554,012 merger shares to former Oncoinvent shareholders, establishing a new share capital of NOK 156,641,128. The combined company plans to provide updates on the merger and its ongoing phase 2 ovarian cancer study in a virtual presentation. This merger is expected to strengthen the company’s position in the biotechnology sector, particularly in cancer treatment, by leveraging Oncoinvent’s expertise in radiopharmaceutical therapies.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent ASA is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Its lead product, Radspherin®, utilizes radium-224 to target micro-metastases post-surgery, offering a modern approach to radiopharmaceuticals without the complexities of biological targeting. The company is actively conducting clinical trials across the US, UK, and Europe, with promising early efficacy data and no serious safety concerns reported.
Average Trading Volume: 83,310
Current Market Cap: NOK44.56M
See more data about BRRGF stock on TipRanks’ Stock Analysis page.